1-4 of 4
Lisle M. Nabell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer

Logan D. Stone, Benjamin B. Kasten, Shilpa Rao, Manuel. L. Gonzalez, Todd M. Stevens, Diana Lin, William Carroll, Benjamin Greene, Lindsay S. Moore, Andrew Fuson, Sherin James, Yolanda E. Hartman, Susan McCammon, Bharat Panuganti, Lisle M. Nabell, Yufeng Li, Mei Li, Luke Bailey, Eben L. Rosenthal, Harishanker Jeyarajan, Carissa M. Thomas, Jason M. Warram
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (18): 4016–4028.
https://doi.org/10.1158/1078-0432.CCR-24-0940
Published: 13 September 2024
View articletitled, Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Open the PDF for Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma

Daniel P. Petrylak, Bernhard J. Eigl, Saby George, Elisabeth I. Heath, Sebastien J. Hotte, David D. Chism, Lisle M. Nabell, Joel Picus, Susanna Y. Cheng, Leonard J. Appleman, Guru P. Sonpavde, Alicia K. Morgans, Pourya Pourhosseini, Ruishan Wu, Laura Standley, Ruslan Croitoru, Evan Y. Yu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 63–73.
https://doi.org/10.1158/1078-0432.CCR-22-3627
Published: 05 January 2024
View articletitled, Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma
Open the PDF for Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer

Eben L. Rosenthal, Jason M. Warram, Esther de Boer, Thomas K. Chung, Melissa L. Korb, Margie Brandwein-Gensler, Theresa V. Strong, Cecelia E. Schmalbach, Anthony B. Morlandt, Garima Agarwal, Yolanda E. Hartman, William R. Carroll, Joshua S. Richman, Lisa K. Clemons, Lisle M. Nabell, Kurt R. Zinn
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (16): 3658–3666.
https://doi.org/10.1158/1078-0432.CCR-14-3284
Published: 13 August 2015
View articletitled, Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer
Open the PDF for Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer in another window
Includes: Multimedia, Supplementary data
Journal Articles

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers

Patricia M. LoRusso, Smitha S. Krishnamurthi, John J. Rinehart, Lisle M. Nabell, Lisa Malburg, Paul B. Chapman, Samuel E. DePrimo, Steven Bentivegna, Keith D. Wilner, Weiwei Tan, Alejandro D. Ricart
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (6): 1924–1937.
https://doi.org/10.1158/1078-0432.CCR-09-1883
Published: 14 March 2010
View articletitled, Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers
Open the PDF for Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral MAPK/ERK Kinase Inhibitor PD-0325901 in Patients with Advanced Cancers in another window